Lord, Abbett & Co
SURF

Lord, Abbett & Co’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Lord, Abbett & Co’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-479,905
Closed -$5.25M – 847
2018
Q3 		$5.25M Buy
479,905
+13,507
+3% +$158K 0.01% 726
2018
Q2 		$7.61M Buy
+466,398
New +$6.75M 0.02% 665

Other funds holding SURF

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lord, Abbett & Co's SURF Position: Q4 2018 in Review

Lord, Abbett & Co sold out of Surface Oncology, Inc. Common Stock (SURF) in Q4 2018, closing a stake of 479,905 shares — an estimated $5.25M sold.

Lord, Abbett & Co first reported a position in SURF in Q2 2018 and held it in 2 quarters. The position peaked at $7.61M in Q2 2018. 50 funds tracked by Wall St. Rank hold SURF as of Q4 2018.

  • Lord, Abbett & Co reported no remaining Surface Oncology, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 479,905 Surface Oncology, Inc. Common Stock shares in Q4 2018, an estimated $5.25M.
  • Lord, Abbett & Co first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Lord, Abbett & Co's Surface Oncology, Inc. Common Stock position peaked at $7.61M in Q2 2018.
  • 50 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q4 2018.

Based on Lord, Abbett & Co's 13F filing for Q4 2018, filed 14 Feb 2019.